CA
NZ
UK
AU
IND
US
…
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Adagene Inc is a NASDAQ‑listed biopharmaceutical company that works on antibody therapeutics and immuno‑oncology; publicly available detail on its programs and platform is limited. Its long‑term growth may be driven by clinical progress of pipeline candidates, validation of its discovery platform, and business development or licensing that extend resources and market reach. Investors may find the company attractive for potential milestone‑driven upside if clinical programs advance and partners are secured.
Key risks include high clinical and regulatory uncertainty, significant cash‑burn and financing needs, intense competition in the antibody/oncology field, and dependence on successful trial outcomes and deal execution.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -17.91M | -33.44M | -17.25M | -79.51M | -71.48M |
| Net income | -17.61M | -33.42M | -18.95M | -79.97M | -73.18M |
| Selling general administrative | 7.08M | 7.27M | 8.67M | 11.87M | 14.44M |
| Selling and marketing expenses | - | - | 0.01M | - | - |
| Gross profit | 7.67M | -0.82M | 18.11M | 9.29M | 10.18M |
| Reconciled depreciation | 0.59M | 0.94M | 1.21M | 1.45M | 1.13M |
| Ebit | -21.49M | -32.59M | -16.16M | -83.92M | -72.36M |
| Ebitda | -20.91M | -31.66M | -14.95M | -81.37M | -70.51M |
| Depreciation and amortization | 0.58M | 0.93M | 1.21M | 2.55M | 1.85M |
| Operating income | -21.44M | -35.95M | -23.72M | -83.92M | -72.36M |
| Other operating expenses | 29.11M | 36.05M | 41.83M | 93.21M | 82.54M |
| Interest expense | 0.46M | 0.85M | 1.11M | 0.69M | 0.36M |
| Tax provision | -0.30M | -0.02M | 1.69M | 0.46M | 1.70M |
| Interest income | 2.30M | 3.80M | 4.28M | 0.38M | 0.08M |
| Net interest income | 1.84M | 2.95M | 3.18M | -0.32M | -0.29M |
| Income tax expense | -0.30M | -0.02M | 1.69M | 0.46M | 1.70M |
| Total revenue | 7.67M | 0.10M | 18.11M | 9.29M | 10.18M |
| Total operating expenses | 29.11M | 36.05M | 41.83M | 93.21M | 82.54M |
| Cost of revenue | - | 0.93M | - | - | - |
| Total other income expense net | 3.53M | 2.51M | 6.46M | 4.41M | 0.89M |
| Net income from continuing ops | -17.61M | -33.42M | -18.95M | -79.97M | -73.18M |
| Net income applicable to common shares | - | - | - | - | -73.21M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 78.26M | 89.27M | 115.73M | 152.40M | 189.51M |
| Other current assets | 2.83M | 2.58M | 3.29M | 4.94M | 4.06M |
| Total liab | 42.91M | 38.74M | 45.17M | 69.31M | 32.95M |
| Total stockholder equity | 35.35M | 50.52M | 70.56M | 83.09M | 156.56M |
| Other current liab | 12.75M | 15.52M | 19.72M | 22.54M | 16.50M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -328.79M | -311.18M | -277.75M | -258.81M | -178.83M |
| Other liab | - | - | - | 0.03M | 0.14M |
| Other assets | - | -0.02M | 0.00M | 0.11M | 0.07M |
| Cash | 74.52M | 85.19M | 109.93M | 143.76M | 174.39M |
| Total current liabilities | 25.17M | 38.18M | 31.46M | 55.08M | 29.82M |
| Current deferred revenue | 3.46M | - | 0.05M | 15.11M | 5.50M |
| Net debt | -68.26M | -66.70M | -87.63M | -115.79M | -166.90M |
| Short term debt | 5.07M | 17.93M | 8.59M | 13.77M | 4.50M |
| Short long term debt | 4.98M | 17.79M | 8.40M | 13.62M | 4.50M |
| Short long term debt total | 6.26M | 18.49M | 22.31M | 27.97M | 7.49M |
| Other stockholder equity | 366.04M | 362.22M | 350.11M | 342.74M | 335.48M |
| Property plant equipment | - | - | - | 2.97M | 3.49M |
| Total current assets | 77.38M | 87.78M | 113.44M | 149.32M | 185.95M |
| Net tangible assets | - | - | - | 83.09M | 156.56M |
| Net receivables | 0.02M | 0.01M | 0.22M | 0.62M | 7.51M |
| Long term debt | 1.14M | 0.42M | 13.54M | 14.15M | 2.99M |
| Accounts payable | 2.88M | 4.24M | 3.09M | 3.67M | 3.32M |
| Accumulated other comprehensive income | -1.91M | -0.53M | -1.80M | -0.85M | -0.09M |
| Non currrent assets other | 0.03M | 0.10M | 0.08M | 0.11M | 0.07M |
| Non current assets total | 0.89M | 1.51M | 2.29M | 3.08M | 3.56M |
| Capital lease obligations | 0.15M | 0.28M | 0.37M | 0.21M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.49M | 1.11M | -0.08M | -0.69M | -2.51M |
| Change to liabilities | - | - | - | 0.00M | 6.33M |
| Total cashflows from investing activities | 0.48M | 1.11M | -0.08M | - | -2.51M |
| Net borrowings | -12.24M | -3.42M | -5.37M | - | -0.70M |
| Total cash from financing activities | 4.45M | 3.77M | -5.37M | 17.82M | 145.36M |
| Change to operating activities | - | - | - | - | 4.36M |
| Net income | -17.61M | -33.42M | -18.95M | -79.97M | -73.18M |
| Change in cash | -10.67M | -24.74M | -33.82M | -30.63M | 99.24M |
| Begin period cash flow | 85.19M | 109.93M | 143.76M | 174.39M | 75.15M |
| End period cash flow | 74.52M | 85.19M | 109.93M | 143.76M | 174.39M |
| Total cash from operating activities | -15.66M | -29.70M | -28.45M | -48.61M | -43.41M |
| Issuance of capital stock | 16.55M | 7.33M | 0.00M | 0.00M | 149.79M |
| Depreciation | 0.59M | 0.93M | 1.21M | 1.45M | 1.13M |
| Other cashflows from investing activities | 0.00M | 0.00M | 0.01M | - | - |
| Dividends paid | - | - | - | - | 4.61M |
| Change to inventory | - | - | - | - | 6.02M |
| Change to account receivables | -0.01M | 0.21M | 0.40M | 3.00M | -3.00M |
| Sale purchase of stock | - | 0.00M | 0.00M | -3.98M | -2.36M |
| Other cashflows from financing activities | 16.55M | -0.14M | 0.01M | 26.15M | 7.63M |
| Change to netincome | - | - | - | - | 19.29M |
| Capital expenditures | 0.02M | 0.03M | 0.09M | 0.69M | 2.51M |
| Change in working capital | -0.78M | -1.89M | -16.55M | 21.94M | 9.35M |
| Stock based compensation | 3.74M | 4.91M | 7.27M | 10.52M | 18.68M |
| Other non cash items | -1.60M | -0.22M | -1.44M | -2.55M | -0.01M |
| Free cash flow | -15.67M | -29.73M | -28.54M | -49.30M | -45.92M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADAG Adagene Inc |
- -% |
2.12 | - | - | 32.73 | 7.27 | 24.61 | 1.12 |
| NVO Novo Nordisk A/S |
1.09 2.72% |
41.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.78 0.69% |
550.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
15.61 1.73% |
919.96 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
| Name | Title | Year Born |
|---|---|---|
| Dr. Peter P. Luo Ph.D. | Co-Founder, CEO & Chairman | 1966 |
| Mr. Man Kin Tam M.B.A. | CFO & Director | 1977 |
| Dr. Fangyong Du Ph.D. | Chief Technology Officer | 1970 |
| Dr. Jc Xu M.D., Ph.D. | Chief Scientific Officer | 1965 |
| Ms. Ami Celeste Knoefler | VP of Investor Relations & Corp. Communications | NA |
| Ms. Ling Zhou | Head of HR | NA |
| Dr. Qinghai Zhao | Chief Manufacturing Officer | 1961 |
| Ms. Yan Li M.B.A. | Sr. VP of Bioinformatics & Information Technology | 1975 |
| Ms. Xiaohong She | Sr. VP & Head of Clinical Operations | 1967 |
| Dr. Guizhong Liu Ph.D. | Head of Biology & Pharmacology | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.88%
Communication Services
+1.14%
Consumer Cyclical
+1.04%
Consumer Defensive
+0.57%
Energy
+0.50%
Financial Services
+0.81%
Financials
+0.24%
Healthcare
+1.35%
Industrials
+1.54%
Real Estate
+0.24%
Technology
+2.32%
Utilities
+0.48%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
-4.40%
Please wait processing your request...